Caribou Biosciences, Inc.
NASDAQ:CRBUBiotechnology
-$0.05 today
- Market cap
- $52.47M
- Beta
- 2.33
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.39
Volume 1.01M
Average 1.83M
CRBU Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Caribou Biosciences, Inc.NASDAQ: CRBU
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue grows, but more slowly than its trailing trend
Q1 FY2026 revenue of $2.4M rose 1.9% year over year, behind the +13.0% change in trailing-twelve-month revenue. Sequentially, it fell 39.2% from the prior quarter. Over 3 fiscal years it compounded at -7.0% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 4 analysts of $8.72M (-21.9%) for the fiscal year ending Dec 2026, a slowdown from the +11.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $2.4M-39.2% QoQ
- Last fiscal yearDec 2025
- $11.16M+11.7% YoY
- LTMMar 2026
- $11.2M+13.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1.9% | -14.5% | -16.4 pp |
| 1 year | +11.7% | -21.9% | -33.5 pp |
| 3-year CAGR | -7.0% | -10.8% | -3.8 pp |
| 5-year CAGR | +53.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 11.16M USD
- Year-over-year change
- +11.7%
- 4-year CAGR
- +3.8%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.16M | +11.7% |
| FY2024 | 2024-12-31 | 9.99M | -71.0% |
| FY2023 | 2023-12-31 | 34.48M | +148.9% |
| FY2022 | 2022-12-31 | 13.85M | +44.3% |
| FY2021 | 2021-12-31 | 9.6M | — |
Revenue vs competitors
How CRBU compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +13.0% is the 4th highest of 7, against a peer median of +13.7%.
- Over three fiscal years its annual growth of -7.0% compares with a peer median of +9.2%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $69.21M USD | +7.4% | -8.8% | |
| LTM Mar 2026 | $32.72M USD | +1033.9% | +111.6% | |
| LTM Mar 2026 | $28.22M USD | +20.1% | +17.1% | |
| LTM Mar 2026 | $16.72M USD | +138.9% | — | |
| LTM Mar 2026 | $13.86M USD | — | — | |
| LTM Mar 2026 | $11.2M USD | +13.0% | -7.0% | |
| FY2025 | €4.48M EUR | -51.3% | -28.3% | |
| LTM Mar 2026 | $2.02M USD | -74.0% | +9.2% | |
| LTM Mar 2026 | $225K USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| Peer median (excluding CRBU) | — | +13.7% | +9.2% | |
Competitors are the stored peer set for CRBU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 9.6M | 13.85M | 34.48M | 9.99M | 11.16M |
| Cost of Revenue | 984K | 3.64M | 3.53M | 3.93M | 3.65M |
| Gross Profit | 8.61M | 10.21M | 30.95M | 6.07M | 7.51M |
| Gross Margin | 89.7% | 73.7% | 89.8% | 60.7% | 67.3% |
| Research & Development | 52.26M | 82.23M | 112.08M | 130.15M | 109.44M |
| Selling, General & Admin | 23.34M | 38.02M | 38.46M | 46.46M | 37.91M |
| Operating Expenses | 75.59M | 116.61M | 147.01M | 172.68M | 143.71M |
| Depreciation & Amortization | 984K | 3.64M | 3.53M | 3.93M | 3.65M |
| EBITDA | (65.61M) | (95.71M) | (98.35M) | (145.19M) | (145.03M) |
| EBITDA Margin | -683.6% | -691.0% | -285.3% | -1452.7% | -1299.7% |
| Operating Income | (66.98M) | (106.4M) | (116.06M) | (166.62M) | (136.19M) |
| Operating Margin | -697.8% | -768.2% | -336.6% | -1667.2% | -1220.5% |
| Interest Income | 148K | 4.6M | 10.7M | 0 | 8M |
| Interest Expense | 8K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 377K | 7.05M | 14.18M | 17.5M | (12.48M) |
| Income Before Tax | (66.6M) | (99.35M) | (101.88M) | (149.11M) | (148.68M) |
| Pre-Tax Margin | -693.9% | -717.3% | -295.5% | -1492.0% | -1332.3% |
| Income Tax Expense | 321K | 70K | 193K | (9K) | (550K) |
| Net Income | (66.92M) | (99.42M) | (102.07M) | (149.11M) | (148.13M) |
| Net Margin | -697.3% | -717.8% | -296.1% | -1491.9% | -1327.4% |
| EPS (Basic) | (1.11) | (1.64) | (1.38) | (1.65) | (1.59) |
| EPS (Diluted) | (1.11) | (1.64) | (1.38) | (1.65) | (1.59) |
| Weighted Avg Shares | 60.26M | 60.8M | 73.81M | 90.32M | 93.39M |
| Weighted Avg Shares (Diluted) | 60.26M | 60.8M | 73.81M | 90.32M | 93.39M |
Caribou Biosciences, Inc.
NASDAQ:CRBU
Intrinsic Alpha fair value
Locked
Current Price
$0.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.